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Obesity and its associated complications constitute serious public health threats in the twenty-first century 1 . Obesity is the leading cause of insulin resistance and type 2 diabetes [2] [3] [4] [5] . Thus, understanding the molecular links between these conditions is crucial for the development of effective treatments for both insulin resistance and type 2 diabetes.
The ER is a sophisticated luminal network for the synthesis, folding and transport of secretory and membrane proteins 6, 7 . Conditions that lead to perturbations in ER homeostasis can create a condition called ER stress, which induces activation of a complex signaling network called the unfolded protein response (UPR) [8] [9] [10] . The UPR cascade is primarily initiated by the type I transmembrane kinases, protein kinase R-like endoplasmic reticulum kinase and inositol-requiring enzyme-1 (IRE1), and a type II transmembrane protein, activating transcription factor-6 (refs. [6] [7] [8] [9] [10] .
IRE1 possesses kinase as well as endoRNase activity 11, 12 . The endoRNase domain of IRE1 cleaves the mRNA of a transcription factor called XBP-1 and initiates the removal of a 26-bp intron from the full-length XBP-1 mRNA. The resulting combination of two mRNA fragments creates a translational frame shift, which leads to the translation of a higher-molecular-weight protein called XBP-1s [13] [14] [15] . XBP-1s is a highly active transcription factor and functions as one of the master regulators of ER folding capacity [8] [9] [10] 16, 17 .
In recent years, we and others have shown that increased ER stress in obesity has a key role in the development of pathologies such as insulin resistance and type 2 diabetes [18] [19] [20] . We have identified XBP-1s as a major regulator of ER folding capacity in obesity and have demonstrated that haploinsufficiency of XBP-1 in mice was sufficient to create severe insulin resistance and diabetes 20 . We have also established a causal link between XBP-1s, ER stress and development of leptin resistance in obesity 21 . More recently, we have shown that there is a severe defect in the ability of XBP-1s to move to the nucleus in obesity conditions 22 . We further documented that this defect is crucial for development of ER stress and type 2 diabetes in obesity 22 .
Forkhead transcription factors of the FoxO subfamily have emerged as a shared component among pathways regulating diverse cellular functions, such as differentiation, metabolism, proliferation and survival [23] [24] [25] . In particular, among the various members of the FoxO subfamily, FoxO1 acts as a cardinal regulator of whole-body energy homeostasis, including hepatic glucose output, adipocyte and muscle differentiation, and feeding behavior in the brain 23, 24 . FoxO1, in coordination with peroxisome proliferator-activated receptor-γ co-activator-1α (encoded by Ppargc1a), increases the gene expression of phosphoenolpyruvate carboxykinase (encoded by Pck1) and glucose-6 phosphatase (encoded by G6pc) and regulates gluconeogenesis 26, 27 . Although this mechanism is beneficial during fasting states for preventing hypoglycemia in healthy people, it is one of the main pathologies that lead to the development of fasting, as well as postprandial, hyperglycemia in insulin-resistant conditions. Activation of insulin receptor signaling, ultimately resulting in phosphorylation and activation of Akt, leads to phosphorylation of FoxO1 on three different residues and is thought to be one of the main mechanisms that is responsible for exclusion of FoxO1 from the nucleus 23, 24 . In addition, other mechanisms such as acetylation [28] [29] [30] , methylation 31 and degradation [32] [33] [34] have been shown to alter FoxO1 activity 23, 24 .
Here we identify a previously unknown mechanism in which XBP1s directly interacts with FoxO1 to promote its degradation by the 26S proteasome system, and we investigate the details and consequences of this interaction and the possibility of increasing XBP-1s action in obese conditions for treatment of glucose intolerance and type 2 diabetes.
RESULTS

XBP-1s interacts with FoxO1 and induces its degradation
Considering the central roles of FoxO1 and XBP-1s in regulating metabolic homeostasis, we sought to investigate whether XBP-1s directly affects FoxO1. To test this possibility, we infected mouse embryonic fibroblasts (MEFs) with a constant dose of FoxO1-expressing adenovirus (Ad-FoxO1) along with increasing doses of XBP-1s-expressing adenovirus (Ad-XBP-1s) and analyzed FoxO1 and XBP-1s protein amounts in total cell lysates and in cytoplasmic and nuclear fractions. When XBP-1s expression was high, FoxO1 protein amounts declined dramatically in total cell lysates as well as in cytoplasmic and nuclear fractions, whereas Foxo1 mRNA levels were unaltered (Fig. 1a) . Furthermore, XBP-1s did not affect the protein levels of other members of FoxO family such as FoxO3a (Fig. 1b) .
Next, to test whether the decrease in FoxO1 protein associated with the presence of XBP-1s resulted from enhanced degradation of FoxO1, we expressed FoxO1 and XBP-1s together in MEFs and subsequently exposed the cells to DMSO or to the 26S proteasome inhibitor MG132 (10 µM) for 2 h. MG132 treatment blocked XBP-1s-induced degradation of FoxO1 (Fig. 1c) , indicating that XBP-1s enhances FoxO1 protein degradation. To document this more directly, we performed a pulse-chase experiment for FoxO1 in the presence or absence of XBP-1s. The degradation rate of FoxO1 was markedly higher in the presence of XBP-1s (Fig. 1d) . We also documented that expression of XBP-1s markedly increased the ubiquitination of FoxO1 (Fig. 1e) .
These observations prompted us to test whether XBP-1s directly binds FoxO1. For this purpose, we expressed FoxO1 and a Flag-tagged XBP-1s (Flag-XBP-1s) in MEFs and also treated one group of cell with MG132 (20 µM) for 2 h to block the degradation of FoxO1. Subsequently, we crosslinked the proteins with the chemical crosslinker dithiobis sulfosuccinimidyl propionate (DSP) and performed immunoprecipitations. We failed to observe any interaction without inhibition of proteasome activity (Fig. 1f) ; this may have been the result of a rapid turnover of the XBP-1s-FoxO1 complex and low FoxO1 amounts in the wholecell lysates from which XBP-1s was immunoprecipitated (Fig. 1f) . However, when we used MG132 to inhibit the 26S proteasome system and crosslinked the proteins with DSP, XBP-1s immunoprecipitation also pulled down FoxO1, indicating that these two proteins are able to interact (Fig. 1f) .
We also performed mammalian two-hybrid assays to further validate the interaction between FoxO1 and XBP-1s ( Supplementary  Fig. 1a,b) . Transfection of Chinese hamster ovary (CHO) cells with both pM-XBP-1s and pVP16-FoxO1 yielded a significantly (P < 0.001) higher luciferase signal when compared to that obtained with transfection with pM-XBP-1s alone (Fig. 1g) . Furthermore, when we used the reverse strategy (pVP16-XBP-1s and pM-FoxO1), the mammalian two-hybrid assay similarly created a significantly (P < 0.0012) higher luciferase signal than that generated by pM-FoxO1 alone (Fig. 1g) . Collectively, our results indicate that XBP-1s directly binds FoxO1 and promotes its protein degradation via the 26S proteasome.
Effect of XBP-1s on FoxO1 is phosphorylation independent
The above experiments were performed in 0.5% FBS-containing medium. Although Akt activity would not be detectable via immunoblotting under these conditions, we attempted to rule out the possibility that low-level basal Akt activity persists, even under the conditions of starvation with 0.5% FBS-containing medium. BEZ235 acts as a highly effective dual inhibitor of phosphoinositide 3-kinase and mammalian target of rapamycin, and we found that it completely inhibits Akt activation when added to the medium ( Supplementary  Fig. 1c ). Treatment of MEF cells with BEZ235 (1 µM, 4 h) after the starvation period slightly increased nuclear amounts of FoxO1 when the cells were infected with Ad-FoxO1 alone (Fig. 1h) , probably owing to inhibition of remnant basal Akt activity. However, when the cells were infected with both Ad-XBP-1s and Ad-FoxO1 and then exposed to BEZ235 compound, nuclear amounts of FoxO1 remained reduced (Fig. 1h) , indicating that the action of XBP-1s on FoxO1 is independent of Akt activation.
To validate this observation further, we first used cells harboring knockouts of both Akt1 and Akt2 (Akt1/2 double-knockout cells). To exclude the possibility that Akt3 might have a role in mediating the XBP-1s-mediated FoxO1 degradation, we infected the cells with increasing doses of Ad-XBP-1s and transfected with a constant dose of FoxO1 while also subsequently treating the cells with a specific Akt inhibitor (Akti-VIII, 20 µM). This system also showed a marked reduction in the FoxO1 protein abundance (Fig. 1i) . However, to more fully prove the hypothesis that XBP-1s-induced FoxO1 degradation is completely independent of FoxO1 phosphorylation, we investigated whether XBP-1s can still lead to the degradation of phosphorylation-resistant FoxO1 (FoxO1-ADA). FoxO1-ADA is mutated on three residues (T24A, S253D and S316A) and is resistant to the effects of Akt (ref. 35) . XBP-1s expression also led to degradation of FoxO1-ADA (Fig. 1j) .
XBP-1s can act independently of insulin receptor signaling
We previously found that reduction of ER stress and increased insulin sensitivity can only be achieved by high XBP-1s expression 20 . Likewise, depletion of FoxO1 was shown to result in increased glucose tolerance and improved metabolic homeostasis, even in mice knocked out for insulin receptor substrate-1 (IRS-1) and IRS-2 specifically in the liver 36 . Given these findings and that nuclear accumulation of Xbp-1s is reduced in states of obesity 22 , we reasoned that if the interaction between XBP-1s and FoxO1 has a dominant role in the regulation of glucose homeostasis in vivo, then XBP-1s expression at a level that is insufficient to modulate ER stress and insulin sensitivity but sufficient to increase its nuclear levels may still lead to improved glucose homeostasis in an appropriate animal model of diabetes. We explored this idea with a series of experiments in which we injected three increasing doses of Ad-XBP-1s or Ad-LacZ into the tail vein of obese, insulin-resistant, diabetic ob/ob mice.
First, we injected 9-week-old ob/ob mice with 1 × 10 7 plaqueforming units (PFU) g −1 of Ad-XBP-1s or Ad-LacZ, which we refer to as a 'low' dose. This low dose of Ad-XBP-1s only slightly increased XBP-1s protein amounts in the liver ( Supplementary Fig. 2a ) but did not significantly alter the expression of XBP-1s target genes known to be involved in the ER folding capacity (such as Dnajb9 (encoding dnaJ homolog subfamily B member 9), Pdia3 (encoding protein disulfide isomerase family A, member 3) and Hspa5 (encoding heat shock 70-kDa protein 5)) (Supplementary Fig. 2b ). Blood glucose concentrations on days 3 and 5 after injection were not significantly reduced in the Ad-XBP-1s-injected group compared with the control mice ( Supplementary Fig. 2c ). Circulating insulin concentrations 9 d after injection were unaffected ( Supplementary Fig. 2d) ; however, a glucose tolerance test (GTT) performed on day 5 after injection documented a marked improvement in glucose tolerance (Supplementary Fig. 2e ). Also, an insulin tolerance test (ITT) on day 7 showed that insulinstimulated disposal of glucose was not different between Ad-LacZ-and Ad-XBP-1s-injected groups (Supplementary Fig. 2f ). To investigate whether this dose of Ad-XBP-1s can effectively increase insulin action, we infused either saline or insulin (0.25 international units (IU) per kg) through the portal vein into the livers of ob/ob mice on day 9 after injection. We detected no differences in insulin-stimulated insulin receptor phosphorylation, IRS-1 tyrosine phosphorylation or Akt Ser473 phosphorylation (Supplementary Fig. 2g ). However, although we found that total and nuclear FoxO1 protein amounts were considerably reduced in the Ad-XBP-1s-injected mice, we found no changes in the abundance of Foxo1 mRNA ( Supplementary Fig. 2h,i) .
We next injected a dose of 4 × 10 7 PFU g −1 (referred to as a 'medium' dose) of Ad-LacZ or Ad-XBP-1s through the tail vein of 7-week-old male ob/ob mice. This medium dose of Ad-XBP-1s injection considerably increased XBP-1s protein amounts in the liver of ob/ob mice compared to the low-dose Ad-XBP-1s-injected ob/ob mice (Fig. 2a) , and with the medium dose of Ad-XBP-1s there was a corresponding two-to threefold increase in the mRNA levels of Dnajb9, Pdia3 and Hspa5 (Fig. 2b) . Blood glucose concentrations were significantly reduced in medium-level XBP-1s-overexpressing mice at fed, 6-h or 14-h fasted states (Fig. 2c) . Moreover, plasma insulin concentrations were significantly lower in the medium-dose Ad-XBP-1s-injected ob/ob mice relative to the control group (Fig. 2d) , and, as documented by GTT, the glucose disposal rate in the medium-dose Ad-XBP-1s-injected group was significantly enhanced when compared with the Ad-LacZ-injected group (Fig. 2e) . However, ITT revealed no alteration in insulin-stimulated glucose clearance from the circulation in the Ad-XBP-1s-injected group relative to controls (Fig. 2f) .
To analyze insulin receptor signaling in the medium-dose Ad-XBP1s-injected group, we infused either saline or insulin (0.25 IU kg −1 ) through the portal vein into the livers of Ad-LacZ-and Ad-XBP-1s-injected ob/ob mice on day 9 after injection and analyzed the activation of insulin receptor, IRS-1 and Akt. We saw no differences between the two groups in terms of insulin-stimulated tyrosine phosphorylation of insulin receptor and IRS-1, nor in phosphorylation of Akt Ser473 (Fig. 2g) . However, we observed a marked decrease in the total and nuclear amounts of FoxO1 protein in the Ad-XBP-1s-injected group (Fig. 2h) , although the mRNA levels were unaltered (Fig. 2i) . In parallel with these observations, the expression of Igfbp1 (encoding insulinlike growth factor-binding protein-1), G6pc, Pck1 and Ppargc1a were also significantly lower in the Ad-XBP-1s-injected group (Fig. 2j) . Corresponding to the substantial suppression of gluconeogenic gene expression, a pyruvate tolerance test revealed that the hyperglycemic response to a pyruvate challenge was markedly lower in the XBP-1s-overexpressing group ( Supplementary Fig. 3a) ; however, glycogen levels in the livers of both groups were similar (Supplementary Fig. 3b ).
In a third group of mice, we used a dose of Ad-XBP-1s or Ad-LacZ at 1.8 × 10 8 PFU g −1 , which we refer to as a 'high' dose. XBP-1s protein amounts were high (Fig. 3a) , and expression of the chaperones such as Dnajb9, Pdia3 and Hspa5 was upregulated 7-to 12-fold (Fig. 3b) . Blood glucose (day 5) and insulin (day 7) concentrations were significantly different between the Ad-LacZ-and Ad-XBP-1s-injected groups (Fig. 3c,d ), whereas glucose disposal from the circulation during a GTT was greatly enhanced in the Ad-XBP-1s-injected group relative to controls (Fig. 3e) .
We also analyzed insulin-induced activation of insulin receptor signaling subsequent to infusion of insulin through the portal vein. Notably, total insulin receptor protein amounts were dramatically lower in the high-dose Ad-XBP-1s-injected ob/ob livers compared to the Ad-LacZ-injected control group (Fig. 3f) . Although the total amount of tyrosine-phosphorylated insulin receptor was significantly lower (P < 0.01, 650%), the ratio of phosphorylated insulin receptor to total insulin receptor was slightly increased (Supplementary Fig. 3c ). Insulin-stimulated tyrosine phosphorylation of IRS-1 was unaltered, but that of IRS-2 was reduced by 60%, whereas Akt Ser473 phosphorylation was significantly increased (350%) (Supplementary Fig. 3c) . Notably, however, insulin receptor signal transduction is driven by the total amount of tyrosine-phosphorylated insulin receptor. Under high levels of XBP-1s expression, the amount of phosphorylated insulin receptor was reduced by 85% in the XBP-1s-expressing ob/ob group relative to the LacZ-expressing controls. Despite this substantial reduction in the total signal generated from insulin receptor in the Ad-XBP-1s-injected mice, insulin-stimulated tyrosine phosphorylation of IRS-1 was unaltered, whereas that of IRS-2 was only reduced by 64%, and Akt Ser473 phosphorylation was increased 370% ( Supplementary  Fig. 3c ), indicating that the insulin receptor-IRS and IRS-Akt axes are actually markedly enhanced. Indeed, when the total ratio of phosphorylated IRS-1 to total IRS1 are divided by the phosphorylated insulin receptor amount, there was a 5.8-fold higher activation of IRS-1 and a 28.8-fold more phosphorylation of Akt Ser473 in the Ad-XBP-1s group relative to the LacZ-expressing controls. Overall then, we conclude that for an equivalent amount of insulin receptor tyrosine phosphorylation there is markedly enhanced activation of downstream parameters in the presence of high XBP-1s expression. Indeed, our previous observations also documented that when XBP-1s is overexpressed in cells, insulin-stimulated IRS activity was greatly enhanced without any alterations in insulin receptor tyrosine phosphorylation 20 . The decrease in levels of total insulin receptor protein and mRNA (Fig. 3f,g ) when XBP-1s is overexpressed is probably a response to increased insulin sensitivity and reduced blood glucose concentrations, aimed at preventing hypoglycemia in these mice.
Total and nuclear FoxO1 protein amounts were decreased by 83% and 86%, respectively, in Ad-XBP-1s-injected mice compared to the Ad-LacZ-injected control mice. The extent of the reduction was lower than that in the previous two XBP-1s-overexpressing groups (Fig. 3h) . However, Foxo1 mRNA levels were not reduced (Fig. 3i) , indicating that FoxO1 protein is post-transcriptionally regulated by XBP-1s. And, finally, G6pc, Pck1 and Ppargc1a expression was significantly suppressed in the Ad-XBP-1s group when compared to Ad-LacZ controls (Fig. 3j) .
Transcription-independent effects of XBP-1s
The above findings indicated that XBP-1s can also regulate glucose homeostasis independently of its action on ER folding capacity and on the insulin signaling system. If this notion is correct, an XBP-1s mutant unable to bind DNA but still able to bind FoxO1 and trigger its degradation should also reduce blood glucose levels and increase glucose tolerance. To test this possibility, we replaced the DNA-binding domain of XBP-1s with an artificial nuclear localization signal (Fig. 4a) and verified the ability of this DNA-binding mutant XBP-1s (∆DBD) to bind FoxO1 and promote its degradation. ∆DBD was able to move to the nucleus as XBP-1s (Fig. 4a) but was unable to activate ER stress element-driven luciferase reporter systems or initiate the transcriptional program (Fig. 4b) . However, Figure 2 Medium-level expression of XBP-1s in ob/ob mice improves glucose homeostasis without altering insulin receptor signaling. Seven-week-old male ob/ob mice were injected with medium dose (4 × 10 7 PFU g −1 ) of Ad-LacZ (n = 6) or Ad-XBP-1s (n = 6) through the tail vein, except for one group of mice injected with low dose (1 × 10 7 PFU g −1 ) of Ad-XBP-1s as indicated in a. ∆DBD retained its capacity to bind (Fig. 4c) and degrade FoxO1 (Fig. 4d) without affecting Foxo1 mRNA levels (Fig. 4e) . To explore whether ∆DBD would reduce blood glucose concentrations in ob/ob mice, and, if so, to what extent that is seen with XBP-1s, we injected a medium dose (4 × 10 7 PFU g −1 ) of Ad-LacZ, Ad-XBP-1s and Ad-∆DBD adenoviruses via tail vein into ob/ob mice. ∆DBD reduced 6-h fasting blood glucose levels to the same extent as did XBP-1s on day 3 after injection (Fig. 4f) . GTT documented that the improvement in glucose tolerance was not significantly different between the XBP-1s-and ∆DBD-injected groups (Fig. 4g) . FoxO1 protein amounts in total lysates were significantly reduced in the XBP-1s-and ∆DBD-expressing groups (Fig. 4h) and, similar to the previous results, Foxo1 mRNA levels were unaltered (data not shown). And although XBP-1s expression significantly increased the mRNA levels of Hspa5, this effect was lost in ∆DBD-overexpressing ob/ob livers (Fig. 4i) . Furthermore, gene expression of Igfbp1, G6pc and Pck1 was significantly reduced in both XBP-1s-and ∆DBD-overexpressing ob/ob livers (Fig. 4j) . These results provide the first evidence, to our knowledge, that XBP-1s, independent of its modulatory effects on ER folding capacity, can regulate glucose homeostasis. We also found that glucose-stimulated insulin secretion is not altered after glucose (2 g per kg body weight) injection (Supplementary Fig. 4) , indicating that enhanced glucose-stimulated insulin secretion is not a contributing factor in the phenotype of Ad-XBP-1s-injected ob/ob mice.
Insulin-independent regulation of metabolism by XBP-1s
Our data thus far indicated that XBP-1s can reduce blood glucose levels independently of its insulin sensitizing effects. This led us to hypothesize that XBP-1s also exerts its effects under conditions of insulin deficiency, or of insulin receptor or IRS-1/2 double deficiency. To test whether XBP-1s would exert an effect in the complete absence of insulin, we injected 8-week-old male C57BL/6 mice with streptozotocin (200 mg per kg body weight) to ablate insulin-producing beta cells and create an insulin-deficient condition. Seven days after streptozotocin injection, blood glucose concentrations of most mice were over 400 mg dl −1 (Supplementary Fig. 5a ), and insulin was not detectable (Fig. 5a) . On the ninth day after streptozotocin injection, we chose the mice with the highest blood glucose levels (~500 mg dl −1 ), and injected them through tail vein with either Ad-LacZ or with Ad-XBP1s. Six days after virus injection, we found that XBP-1s overexpression had significantly reduced blood glucose levels in the fed state in these diabetic mice (Fig. 5b) . Furthermore, 8 d after virus injection, blood glucose amounts were reduced to euglycemia in the Ad-XBP-1s Error bars are means ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001.
group after 12 h of fasting (221.0 ± 17.1 versus 109.2 ± 12.4 mg dl −1 , P < 0.001) (Fig. 5b) . These results indicate that XBP-1s has the ability to reduce blood glucose levels even in the complete absence of insulin. Total and nuclear FoxO1 amounts in the liver were significantly lower in the Ad-XBP-1s-injected streptozotocin-treated group compared to the Ad-LacZ-injected, streptozotocin-treated control group (Fig. 5c) . Furthermore, mRNA levels of Igfbp1, G6pc and Pck1 were significantly lower in the XBP-1s-overexpressing, streptozotocininjected group (Fig. 5d) . Next, we overexpressed XBP-1s in the liver of mice with liver-specific knockout of insulin receptor (LIRKO mice) by tail vein injection of Ad-XBP-1s or Ad-LacZ. As reported previously 37 , insulin receptor amounts were dramatically reduced in the liver of LIRKO (Insr flox/flox ; Alb-Cre) mice when compared with amounts in the Insr flox/flox mice (Fig. 5e) . GTT performed on day 4 after injection showed that XBP-1s expression led to significant increases in glucose tolerance (Fig. 5e) . Insulin-stimulated glucose disposal was not significantly altered during ITT (Supplementary Fig. 5b ). Similar to the results obtained in the ob/ob models, FoxO1 protein amounts were significantly reduced in the Ad-XBP-1s-injected LIRKO mice, although basal Akt phosphorylation was not altered (Fig. 5f) . Levels of mRNA of Igfbp1, G6pc and Pck1 were all significantly lower in the XBP-1s-overexpressing LIRKO mice compared to the Ad-LacZ-injected LIRKO mice (Fig. 5g) , whereas chaperone gene expression was significantly upregulated to similar levels that are seen with medium-level XBP-1s expression in the ob/ob mice (Supplementary Fig. 5c ).
We next repeated the same experiment in liver-specific IRS-1/2 double-knockout mice, which lack both IRS-1 and IRS-2 in the liver (Fig. 5h) . As in LIRKO mice, overexpression of XBP-1s in the livers of the double-knockout mice led to a significant increase in glucose tolerance (Fig. 5h) and reduced FoxO1 protein abundance (Fig. 5i) . Performance of ITT revealed no differences between the XBP-1s-expressing group and the LacZ-expressing control group (Supplementary Fig. 5d ). In parallel with the other XBP-1s overexpression models, mRNA levels of Igfbp1, G6pc and Pck1 were significantly reduced (Fig. 5j) , and the gene expression of the chaperones was markedly upregulated, which was at a similar level to that seen with medium-level XBP-1s expression in the ob/ob mice (Supplementary Fig. 5e ).
FoxO1-dependent XBP-1s action in the liver
If the regulatory effects of low or medium levels of XBP-1s expression on glucose homeostasis rely mainly on the ability of XBP-1s to degrade FoxO1, it would be expected that medium levels of XBP-1s expression should have no further effect on glucose homeostasis when FoxO1 is depleted in the liver. To evaluate this possibility, we overexpressed XBP-1s in the liver while simultaneously depleting FoxO1 with an adenovirus that expresses FoxO1-targeting shRNA (Ad-shFoxO1). The first group of ob/ob mice was injected with Ad-LacZ (the control virus for Ad-XBP-1s) and Ad-shGFP (control virus for Ad-shFoxO1), the second group with Ad-XBP-1s plus Ad-shGFP, the third group with Ad-shFoxO1 and Ad-LacZ, and the fourth group with Ad-XBP-1s and Ad-shFoxO1. Analysis of blood glucose concentrations on day 7 after injection revealed that ob/ob mice in which either XBP-1s was overexpressed, FoxO1 was depleted or XBP-1s was overexpressed plus FoxO1 was also depleted, had significantly lower blood glucose concentrations when compared with the control ob/ob group (Ad-LacZ plus Ad-shGFP) (Fig. 6a) . However, we saw no difference in the blood glucose concentrations between these three groups, indicating that XBP-1s cannot further reduce blood glucose levels in the absence of FoxO1.
GTT showed that glucose tolerance was also enhanced to similar levels in the ob/ob mice with overexpression of XBP-1s, depletion of FoxO1 or both (Fig. 6b) . FoxO1 protein amounts were similarly significantly lowered in Ad-XBP-1s-injected, Ad-shFoxO1-injected and Ad-XBP-1s-and Ad-shFoxO1-injected groups (Fig. 6c) ; however, Foxo1 mRNA levels were only reduced in the FoxO1-depleted and XBP-1s-overexpressing plus FoxO1-depleted groups (Fig. 6d) . Expression of FoxO1 target genes, such as Igfbp1 and Ppargc1a, was significantly downregulated in XBP-1s-overexpressing, FoxO1-depleted and XBP-1s-overexpressing plus FoxO1-depleted groups, in which FoxO1 levels were markedly reduced (Fig. 6e) . However, mRNA levels for XBP-1s target genes were only upregulated in the XBP-1s-overexpressing groups (Fig. 6f) and not in those with only depletion of FoxO1. Collectively, these results indicate that the regulatory effects of medium levels of XBP-1s expression are primarily dependent on the ability of XBP-1s to induce protein degradation of FoxO1.
Previous studies have shown that in lean mice with liver-specific deletion of the Foxo1 gene, blood glucose levels were unaltered under fed conditions. However, following 48 h of starvation, these mice had about a 30% decrease in their blood glucose levels, owing to an inability to upregulate gluconeogenesis 38 . To investigate whether XBP-1s would produce a similar phenotype, we injected medium-dose (4 × 10 7 PFU g −1 ) Ad-LacZ and Ad-XBP-1s into the tail vein of WT lean mice. Overexpression of XBP-1s did not lead to alteration in blood glucose concentrations, GTT or ITT ( Supplementary  Fig. 6a-c) . However, when the mice were starved for 48 h starting on day 4 after injection, the XBP-1s-overexpressing group had significantly lower blood glucose concentrations (22%, P < 0.05) relative to controls (Supplementary Fig. 6d ).
Depletion of XBP-1s increases FoxO1 levels in the liver
To investigate whether deficiency of XBP-1 in the liver would lead to accumulation of FoxO1 in the liver and thus create glucose and Pck1 mRNA levels (j) in the liver of adenovirus-injected DKO mice on day 8 after the injections. Error bars are means ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001.
intolerance, we used the Xbp1 flox/flox mouse model and depleted XBP-1 protein by tail vein injection of an adenovirus expressing Crerecombinase (Ad-Cre), whereas injection of Ad-LacZ was used as a control. We first injected lean Xbp1 flox/flox mice (fed on a normal diet) with Ad-Cre and Ad-LacZ at 6 weeks of age. We then followed these mice for 5 weeks after injection but did not detect any alterations in blood glucose and in GTT ( Supplementary  Fig. 6e,f) . This was probably due to the fact that the organism can cope with deficiency of XBP-1 under normal conditions; in other words, in the absence of ER stress, there is not much need for XBP-1s. Indeed, our previous work documented that Xbp1 +/− mice do not develop glucose intolerance or insulin resistance when they are fed a normal diet 20 . Next, we placed the Xbp1 flox/flox mice on a high-fat diet at 3 weeks of age; after 4 weeks of high-fat diet feeding, we injected the Xbp1 flox/flox mice through tail vein with Ad-Cre or Ad-LacZ. To investigate whether Ad-Cre injection completely eliminates XBP-1 expression, we administered tunicamycin (3 mg per kg body weight, intraperitoneal) to the mice on day 15 after injection. We found that a marked increase in the levels of XBP-1s protein in the control group was blocked by injection of Ad-Cre, indicating that Ad-Cre expression led to almost complete deletion of XBP-1 in the liver of Xbp1 flox/flox mice (Supplementary Fig. 7a) .
Depletion of XBP-1 for 14 d resulted in a significant (P < 0.01) increase in 6-h fasted blood glucose concentrations ( Supplementary  Fig. 7b ). Circulating insulin levels concentrations were significantly (P < 0.05) upregulated in the Ad-Cre-injected group by 14 d after injection (Supplementary Fig. 7c) . A GTT done on day 17 revealed that Ad-Cre-injected mice developed markedly higher levels of glucose intolerance (Supplementary Fig. 7d) , and glucose clearance from circulation during ITT (day 24) was substantially reduced in XBP-1-depleted group (Supplementary Fig. 7e) . On day 30, we infused mice through the portal vein with insulin and analyzed the activation of the insulin receptor signaling system. We found that insulin-stimulated tyrosine phosphorylation of the insulin receptor was significantly (P < 0.05) reduced (Supplementary Fig. 7f ), whereas we saw no significant changes in IRS-1 tyrosine phosphorylation ( Supplementary  Fig. 7f) . Furthermore, we also observed a significant (P < 0.05) decrease in insulin-stimulated Akt Ser473 phosphorylation ( Supplementary  Fig. 7f ). To investigate whether we could dissect out the effects of insulin signaling and XBP-1s on FoxO1 in this model, we used another group of Xbp1 flox/flox mice and undertook studies of insulin receptor signaling at a relatively early time point (day 20). In these mice, insulin receptor signaling was again substantially reduced compared to the Ad-LacZ-injected Xbp1 flox/flox mice (data not shown). Total and nuclear amounts of FoxO1 substantially accumulated more in the liver of the Ad-Cre-injected Xbp1 flox/flox mice compared to the Ad-LacZ-injected Xbp1 flox/flox mice (Supplementary Fig. 7g ). Finally, we analyzed the gene expression pattern of gluconeogenic genes and found that G6pc gene expression was significantly (P < 0.05) upregulated in the Ad-Cre-injected Xbp1 flox/flox mice, whereas gene expression of Pck1 and Ppargc1a was unaltered (Supplementary Fig. 7h ).
DISCUSSION
In recent years, we and others have demonstrated that increased ER stress that is associated with obesity has a key role in the development of several pathologies, such as insulin resistance and type 2 diabetes, and also of leptin resistance in the brain [18] [19] [20] [21] 39 . Our findings have revealed that XBP-1 is an essential factor for the organism to maintain glucose homeostasis under conditions of high calorie intake and obesity 21 .
To date, the role of XBP-1s in metabolic homeostasis has been believed to be restricted to the ability of this transcription factor to upregulate the expression of genes involved in the improvement of ER folding capacity, thus increasing insulin sensitivity. Our current results add another dimension to XBP-1s and provide evidence that this protein can also regulate glucose homeostasis independently of its ability to regulate the ER folding capacity and to reduce ER stress. Here we have shown that XBP-1s directly binds FoxO1 and promotes its degradation through the 26S proteasome pathway, even when three sites required for the exclusion of FoxO1 from the nucleus by Akt are mutated. We have recently shown that the migration of XBP-1s to the nucleus is severely impaired in obesity conditions 22 , and our results here show this defect is a central pathology for development of hyperglycemia, as reinstatement of XBP-1s action in liver of severely obese and diabetic mice is enough to establish euglycemia. Furthermore, we have previously shown that insulin signaling increases XBP-1s nuclear translocation 22 . Notably, the role of insulin receptor signaling on XBP-1s activity is different in mice compared to lower organisms such as Caenorhabditis elegans 40 , in which loss of Daf-2 (the insulin receptor homolog), contrary to the situation in mice, leads to an increase in the activity of the insulin receptor-IRE-1-XBP-1 axis 40 .
One of our other unexpected findings is the ability of a DNAbinding-defective mutant XBP-1s to increase glucose tolerance and reduce blood glucose concentrations in ob/ob mice when it is overexpressed in liver tissue. XBP-1s is thought to mediate its effects by activation of a complex transcriptional program. Our results provide a key piece of evidence that XBP-1s, in addition to triggering the transcriptional program, can regulate crucial processes in the cell via its interaction with other proteins. We also show that XBP-1s possesses antigluconeogenic activity through degradation of FoxO1. Moreover, XBP-1s can suppress gluconeogenic gene expression in the liver and can improve glucose tolerance without concomitant alterations in insulin sensitivity. For example, experiments performed with low or medium expression of XBP-1s in ob/ob mice do not reveal increased insulin sensitivity but result in markedly reduced blood glucose and greatly enhanced glucose tolerance; however, these events are accompanied by substantial reductions of FoxO1 amounts in nuclear fractions of the liver. Likewise, XBP-1s is capable of improving glucose tolerance in LIRKO mice or in liver-specific IRS-1/2 double-knockout mice. More notably, XBP-1s overexpression in the liver of streptozotocin-treated mice, a model of type 1 diabetes, leads to a considerable decrease in blood glucose concentrations in the fed state and to euglycemia in the fasted state. These results collectively indicate that increasing the activity of XBP-1s in the liver may be beneficial not only for individuals with insulin-resistant type 2 diabetes but also for those with insulindeficient type 1 diabetes.
In contrast, high XBP-1s expression is associated with greatly increased insulin sensitivity. Thus, ligand binding and phosphorylation of the insulin receptor in the presence of high levels of XBP-1s leads to 28.8-fold greater downstream activation of Akt, compared to that seen in the control group. In parallel, however, insulin receptor protein amounts are markedly downregulated when XBP-1s is expressed in high amounts, in effect preventing the hypoglycemia that might otherwise be induced by the increased insulin sensitivity.
Uncovering the exact molecular mechanisms of XBP-1s-induced degradation of FoxO1 will require further investigation. Our current working hypothesis is that, by directly interacting with FoxO1, XBP-1s drags FoxO1 to the 26S proteasome system. Our preliminary observations show that XBP-1s has a very short half-life, which is around 10 min (data not shown); however, FoxO1 has a much longer half-life (~2 h) than XBP-1s (Fig. 1) . We propose that during the very fast shuttling of XBP-1 from the cytoplasm to the nucleus, and subsequently from the nucleus to the 26S proteasome, the interaction between FoxO1 and XBP-1s also directs FoxO1 to the 26S proteasome system, thus leading to its degradation. In addition, ER stress was previously linked to development of inflammation. Recently, it was shown that macrophages that are resident in the liver lead to activation of Toll-like receptor 4 signaling in obesity and an increase of FoxO1 accumulation in the liver 41 . It is also possible that increased XBP-1s expression may reduce the inflammation and lead to a reduction in the activity of macrophages in the liver and also contribute to the exclusion of FoxO1 from the nucleus by using this pathway.
We currently do not know whether the XBP-1s-FoxO1 interaction has a major role in the exclusion of FoxO1 from the nucleus, and thus its inhibition, under physiological conditions, such as postprandial states. However, the link between XBP-1s and FoxO1 might lead to the development of new therapeutic approaches for the treatment of obesity-induced type 2 diabetes. Development of insulin resistance blocks the ability of insulin receptor signaling to exclude FoxO1 from the nucleus, and, despite extensive research efforts, attempts to inhibit FoxO1 by increasing the sensitivity of insulin receptor signaling pathway has not been successful. The newly uncovered function of XBP-1s could be exploited therapeutically to bypass insulin resistance and might provide an alternate approach to exclude FoxO1 from nucleus and thus help in preventing hyperglycemia.
Furthermore, insulin resistance probably developed as a protective mechanism to prevent further fattening when an animal is consuming high levels of calories and to help in extending the life span of the animal. One of the best-known modifications that extend life is inhibition of insulin receptor signaling 24, 42, 43 . This is observed not only in lower organisms but also in mammalian systems, as exemplified by the report that adipocyte-specific depletion of the insulin receptor 44 , or brain-specific depletion of IRS-2, substantially increases life span 45 . Our results indicate that blood glucose levels of insulin-resistant mice can be regulated without increasing insulin sensitivity by promoting the interaction of XBP-1s with FoxO1. Therapies such as the use of peptides, which can mimic the domain of XBP-1s that interacts with FoxO1, or alternative approaches such as the use of small molecules that induce moderate increases in XBP-1s levels, could hold great potential for the treatment of type 2 diabetes without increasing insulin sensitivity. Moderate activation of XBP-1s in obese individuals could be highly beneficial for the person without creating the possible side effects of enhanced insulin sensitivity.
Finally, our studies also suggest that defective XBP-1s nuclear translocation in obesity conditions is one of the mechanisms that contribute to accumulation of FoxO1 in the nucleus 46 . XBP-1 and FoxO1 have key roles in many disease states, including metabolism, cancer, neurodegeneration, differentiation and immunology [23] [24] [25] . We believe that convergence of the pathways associated with these two proteins will provide unique insights in diverse fields and will help in understanding the molecular mechanisms of key biological processes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
